0.00
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hydration Pharmaceuticals Co
Its shares trade on ASX under the ticker HPC.AX. It has been listed since 14 December 2021. In the fiscal year to 31 December 2024, it reported revenue of $3.2m and net income of $2.7m. At that date it held total assets of $5.0m and shareholders' equity of $2.7m.
The Hydration Pharmaceuticals Co. Ltd. markets and sells a range of liquid, tablet and powder healthy hydration solutions products. The firm is focused on the sale and distribution of Hydralyte, which includes a product range of electrolyte-rich tablets, liquids, and powders. The firm markets and sells a range of liquid, tablet, and powder healthy hydration solutions products in the North American markets of Canada and the United States, under the Hydralyte brand. The firm operates as a wholesale supplier and online retailer of Hydralyte products in North America. The firm has a sales footprint in various markets, including the United States, Canada, China, and the United Kingdom. Its subsidiaries include Hydration Pharmaceuticals Trust, Hydration Pharmaceuticals Canada, Hydralyte LLC, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 14 Dec 2021
- Website
- hydralyte.com ↗
Leadership
Pay as last reported
- Mr. Adem KarafiliNon-Executive Chairman of the Board, since 2018
- Mr. Oliver BakerChief Executive Officer, Managing Director, since 2024
- Ms. Victoria NadalinCompany Secretary
- Mr. Nicholas BerryNon-Executive Director
- Mr. Joseph ConstableNon-Executive Director
- Ms. Margaret HardinNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hydration Pharmaceuticals Co Ltd markets Hydralyte products in North America with strong sales in Canada and the US.
- The company operates as a wholesale supplier and online retailer for Hydralyte in North America.
- Hydration Pharmaceuticals has a sales footprint across the United States, Canada, China, and the UK.
Weaknesses
- Hydration Pharmaceuticals Co Ltd is listed on the Australian stock exchange since December 2021.
- The company's business focuses on a single product range, Hydralyte.
- Hydration Pharmaceuticals operates primarily in the Consumer Staples sector.
Opportunities
- Hydration Pharmaceuticals can expand Hydralyte sales into new markets like China and the UK.
- The company has potential to grow its online retail presence in North America.
- Hydration Pharmaceuticals may increase its wholesale distribution in the United States.
Threats
- Hydration Pharmaceuticals faces competition from other hydration product brands in North America.
- The company's reliance on Hydralyte could be a risk if market preferences shift.
- Hydration Pharmaceuticals operates in a highly competitive Consumer Staples sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.